Built on a foundation of longitudinal patient data
Accurate confirmation of medication ingestion
Validated against plasma blood levels
20% - 60% improvements according to blood levels
Rich data fuels predictive insights
Over 1 Million behavioral interactions with IMA
In drug development, we are defining new methodologies and enrichment strategies
Clear value is essential in understanding the application of new technology. AiCure’s value is structured around four key pillars: data integrity; lower variability; predictive composite measures; and increases in statistical power. Incorporating these data pillars into study design allows for faster, smaller trials. AiCure is also demonstrating significant results by introducing new trial methodologies such as placebo lead-in periods, micro-reimbursements, and other approaches directly correlated with patient engagement and clinical endpoints.
For payors, we are reducing medical costs and waste Medication
adherence is one of the few parameters in healthcare that is directly linked to medical costs. AiCure has demonstrated significant savings for some of the largest payors and states by ensuring high-risk patient populations stay on therapy.
For science and the healthcare industry, we are developing novel clinical endpoints through computational diagnostics
AiCure is pioneering a new set of tools to help researchers and clinicians understand and predict how patients respond to treatment. Advances in artificial intelligence allow computers to capture physiological datapoints that characterize expressivity, psychomotor function, and cognition. Whether a patient has schizophrenia or congestive heart failure, the degree to which they are able to adhere and respond to treatment depends in great part on their mood, their ability to move and to concentrate. AiCure is leading a multi-stakeholder R&D effort with industry and academia to develop these transdiagnostic domains and novel sensitive endpoints.
Building a High-Tech, High-Touch Model for Drug Management
Caroline Carney, MD, MSc Caroline Carney, MD, MSc, is the chief medical officer for Magellan Rx Management, the pharmacy…
AiCure’s client base sees uptick as the industry looks to reduce risk
AiCure’s client base sees uptick as the industry looks to reduce risk By Maggie Lynch December 12,…
AiCure's Revenue Soars as it Bolsters Client List and Executive Team
NEW YORK, Dec. 3, 2018 /PRNewswire/ — AiCure, a behavioral data analytics company targeting the healthcare…
An Insight Of AI’s Penetration In Drug Development Market
Yiannis Mouratidis – Contributor, Science Different universes converge in the path of AI-based drug developmentDEEP KNOWLEDGE VENTURES A recent article about…
5 Q’s for Adam Hanina, CEO of AiCure
The Center for Data Innovation spoke with Adam Hanina, chief executive officer of AiCure, a healthcare software company based in…
Intellectual property - Over 100 patents filed